From Nobel Prize to clinical practice: An update on messenger RNA-based therapies for lipid disorders

Ian R Hamilton-Craig

From Nobel Prize to clinical practice: An update on messenger RNA-based therapies for lipid disorders

Ian R Hamilton-Craig

College of Medicine and Public Health

Research output: Contribution to journal › Article › peer-review

Abstract

The biological mechanism of gene silencing by messenger RNA (mRNA) inhibition has been harnessed to develop therapies to target specific proteins, such as those involved in lipid metabolism. The first of these, inclisiran, is available in Australia for reducing levels of LDL-cholesterol and is PBS listed for people with familial and nonfamilial hypercholesterolaemia.

Original language	English
Pages (from-to)	32-37
Number of pages	6
Journal	Medicine Today
Volume	25
Issue number	7
Publication status	Published - Jul 2024

Keywords

Messenger RNA
Lipids
Inclisiran

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://medicinetoday.com.au/mt/2024/july/regular-series/nobel-prize-clinical-practice-update-messenger-rnabased-therapies-lipid-disordersLicence: In Copyright

Cite this

@article{5dea9cd4a4c64f608dd92e683082acf4,

title = "From Nobel Prize to clinical practice: An update on messenger RNA-based therapies for lipid disorders",

abstract = "The biological mechanism of gene silencing by messenger RNA (mRNA) inhibition has been harnessed to develop therapies to target specific proteins, such as those involved in lipid metabolism. The first of these, inclisiran, is available in Australia for reducing levels of LDL-cholesterol and is PBS listed for people with familial and nonfamilial hypercholesterolaemia.",

keywords = "Messenger RNA, Lipids, Inclisiran",

author = "Hamilton-Craig, {Ian R}",

year = "2024",

month = jul,

language = "English",

volume = "25",

pages = "32--37",

journal = "Medicine Today",

issn = "1443-430X",

publisher = "Medicine Today",

number = "7",

}

TY - JOUR

T1 - From Nobel Prize to clinical practice

T2 - An update on messenger RNA-based therapies for lipid disorders

AU - Hamilton-Craig, Ian R

PY - 2024/7

Y1 - 2024/7

N2 - The biological mechanism of gene silencing by messenger RNA (mRNA) inhibition has been harnessed to develop therapies to target specific proteins, such as those involved in lipid metabolism. The first of these, inclisiran, is available in Australia for reducing levels of LDL-cholesterol and is PBS listed for people with familial and nonfamilial hypercholesterolaemia.

AB - The biological mechanism of gene silencing by messenger RNA (mRNA) inhibition has been harnessed to develop therapies to target specific proteins, such as those involved in lipid metabolism. The first of these, inclisiran, is available in Australia for reducing levels of LDL-cholesterol and is PBS listed for people with familial and nonfamilial hypercholesterolaemia.

KW - Messenger RNA

KW - Lipids

KW - Inclisiran

UR - http://www.scopus.com/inward/record.url?scp=85199142919&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85199142919

SN - 1443-430X

VL - 25

SP - 32

EP - 37

JO - Medicine Today

JF - Medicine Today

IS - 7

ER -

From Nobel Prize to clinical practice: An update on messenger RNA-based therapies for lipid disorders

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this